The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Jan. 12, 2016
Applicant:

Shire Human Genetic Therapies, Inc., Lexington, MA (US);

Inventors:

Dennis Keefe, Wilmington, MA (US);

Michael Concino, Bolton, MA (US);

Michael Heartlein, Boxborough, MA (US);

Serene Josiah, Cambridge, MA (US);

Bettina Strack-Logue, Somerville, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 38/17 (2006.01); A61K 49/00 (2006.01); C07K 7/08 (2006.01); A61K 47/64 (2017.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/47 (2013.01); A61K 38/1709 (2013.01); A61K 47/645 (2017.08); A61K 49/0008 (2013.01); C07K 7/08 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0306 (2013.01); A61K 38/00 (2013.01); C07K 2319/07 (2013.01); C07K 2319/10 (2013.01);
Abstract

The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.


Find Patent Forward Citations

Loading…